New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?
作者信息
Mazzola Rosario, Cuccia Francesco, Figlia Vanessa, Giaj-Levra Niccolò, Nicosia Luca, Ricchetti Francesco, Rigo Michele, Pasinetti Nadia, Salgarello Matteo, Alongi Filippo
机构信息
Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy.
Department of Radiation Oncology, Ospedale di Esine - ASL Vallecamonica-Sebino, Esine, Italy.
出版信息
Transl Androl Urol. 2019 Dec;8(Suppl 5):S538-S541. doi: 10.21037/tau.2019.12.34.
Abstract
摘要
相似文献
1
New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?
Transl Androl Urol. 2019 Dec;8(Suppl 5):S538-S541. doi: 10.21037/tau.2019.12.34.
2
Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy.
Br J Urol. 1991 Jun;67(6):626-31. doi: 10.1111/j.1464-410x.1991.tb15228.x.
3
Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.
Urology. 2007 Nov;70(5):950-5. doi: 10.1016/j.urology.2007.06.1119.
4
Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy.
Eur Urol. 2018 Jul;74(1):107-114. doi: 10.1016/j.eururo.2017.11.024. Epub 2017 Dec 10.
5
Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era.
Urology. 2005 Mar;65(3):528-32. doi: 10.1016/j.urology.2004.10.041.
6
Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
J Urol. 2005 Apr;173(4):1150-5. doi: 10.1097/01.ju.0000155158.79489.48.
7
Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52. doi: 10.1016/s0360-3016(96)00590-1.
8
Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
Int J Oncol. 2013 Jan;42(1):109-17. doi: 10.3892/ijo.2012.1694. Epub 2012 Nov 13.
9
Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Urology. 1996 Aug;48(2):249-60. doi: 10.1016/S0090-4295(96)00167-7.
10
The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.
J Urol. 1994 Nov;152(5 Pt 2):1821-5. doi: 10.1016/s0022-5347(17)32394-7.
引用本文的文献
1
Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
Medicina (Kaunas). 2023 Aug 9;59(8):1442. doi: 10.3390/medicina59081442.
2
The F-PSMA-1007 PET/CT performance on metastasis status and therapy assessment in oligo-metastasis prostate cancer.
Front Oncol. 2022 Aug 26;12:935979. doi: 10.3389/fonc.2022.935979. eCollection 2022.
3
1.5T MR-Guided Daily Adaptive Stereotactic Body Radiotherapy for Prostate Re-Irradiation: A Preliminary Report of Toxicity and Clinical Outcomes.
Front Oncol. 2022 Apr 13;12:858740. doi: 10.3389/fonc.2022.858740. eCollection 2022.
4
Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy.
Radiol Med. 2022 May;127(5):560-570. doi: 10.1007/s11547-022-01479-4. Epub 2022 Mar 26.
5
Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT.
Radiat Oncol. 2022 Jan 29;17(1):19. doi: 10.1186/s13014-022-01989-5.
6
Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting.
Radiol Med. 2022 Feb;127(2):206-213. doi: 10.1007/s11547-021-01435-8. Epub 2021 Nov 30.
7
Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer.
Radiat Oncol. 2021 Jun 30;16(1):125. doi: 10.1186/s13014-021-01849-8.
8
Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.
Radiat Oncol. 2021 Jun 23;16(1):114. doi: 10.1186/s13014-021-01839-w.
9
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance.
Med Oncol. 2021 May 18;38(6):72. doi: 10.1007/s12032-021-01518-6.
10
Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Radiat Oncol. 2021 May 12;16(1):88. doi: 10.1186/s13014-021-01808-3.
本文引用的文献
1
Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
BJU Int. 2020 Feb;125(2):206-214. doi: 10.1111/bju.14944. Epub 2019 Nov 29.
2
Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis.
Strahlenther Onkol. 2020 Mar;196(3):213-221. doi: 10.1007/s00066-019-01523-9. Epub 2019 Sep 26.
3
The emerging role of PET-CT scan after radical prostatectomy: still a long way to go.
Lancet Oncol. 2019 Sep;20(9):1193-1195. doi: 10.1016/S1470-2045(19)30501-7. Epub 2019 Jul 30.
4
F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Lancet Oncol. 2019 Sep;20(9):1286-1294. doi: 10.1016/S1470-2045(19)30415-2. Epub 2019 Jul 30.
5
(Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy.
Cancer Radiother. 2019 Jun;23(3):194-200. doi: 10.1016/j.canrad.2018.09.003. Epub 2019 May 12.
6
A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
Eur Urol Oncol. 2019 Feb;2(1):47-76. doi: 10.1016/j.euo.2018.09.010. Epub 2018 Oct 24.
7
Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy.
Urology. 2019 Jul;129:165-171. doi: 10.1016/j.urology.2018.12.055. Epub 2019 Mar 27.
8
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study.
World J Urol. 2019 Dec;37(12):2631-2637. doi: 10.1007/s00345-019-02717-7. Epub 2019 Mar 11.
9
Clinical implications of PET/CT in prostate cancer management.
Transl Androl Urol. 2018 Oct;7(5):844-854. doi: 10.21037/tau.2018.08.26.
10
Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Eur Urol. 2018 Oct;74(4):455-462. doi: 10.1016/j.eururo.2018.06.004. Epub 2018 Jun 29.
Zotero 插件